V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240002415 | 240007083 | 1.62 | 83 | null | 2018-10-21 | 2018-10-30 | CHLORAMBUCIL + RITUXIMAB | 02 | null | TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 100564305 |
| 240002417 | 240007085 | null | null | Curative (C) | null | 2019-02-04 | null | null | N | IMATINIB | 101782255 |
| 240002418 | 240007086 | 1.79 | 57.9 | Disease modification (D) | 2021-06-08 | 2021-06-23 | null | 01 | null | MUK 9 TRIAL | 100515222 |
| 240002420 | 240007087 | 1.59 | 53.9 | null | null | 2020-05-04 | Vinblastine | null | null | CYTARABINE + DAUNORUBICIN | 101198817 |
| 240002421 | 240007088 | 1.76 | 52.5 | Adjuvant (A) | null | 2018-11-17 | AML MyeChild 01 A Mitozantrone/Cytarabine + GO | null | N | AXITINIB | 100148329 |
| 240002424 | 240007090 | 1.72 | 36.4 | 03 | 2020-03-31 | 2020-04-16 | CNS LGG2004 03 vinc + carbo | 02 | N | GILTERITINIB | 100682624 |
| 240002426 | 240007092 | 1.63 | 86.2 | Curative (C) | null | 2017-10-06 | Bortezomib + Cyclophos + Dex | null | null | CAR-T AXICABTAGENE CILOLEUCEL + CYCLOPHOSPHAMIDE + FLUDARABINE | 100918603 |
| 240002428 | 240007094 | 1.65 | 76.4 | Curative (C) | 2016-07-16 | 2016-10-17 | CHOP | 02 | N | VENETOCLAX | 101526696 |
| 240002429 | 240007095 | 1.64 | 67.4 | null | 2018-08-04 | 2019-02-01 | Cytarabine HD + Methotrexate HD | 01 | null | ALL UKALL2011 AUG BFM CONS C | 100820324 |
| 240002430 | 240007096 | 1.69 | 61.9 | null | null | 2017-11-29 | IMATINIB | null | null | TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 100702960 |
| 240002431 | 240007097 | 1.89 | 88 | Curative (C) | 2020-02-19 | 2020-02-19 | null | null | null | CYTARABINE HIGH DOSE | 101729725 |
| 240002434 | 240007099 | 1.63 | 92.8 | null | null | 2018-04-14 | FLAIR trial | null | null | IBRUTINIB | 100812746 |
| 240002437 | 240007100 | 1.84 | 63.8 | Curative (C) | null | 2022-01-09 | CYTARABINE + DAUNORUBICIN + Gemtuzumab Ozogamicin | 01 | N | CYTARABINE + DAUNORUBICIN | 101505664 |
| 240002438 | 240007101 | 1.51 | 94 | Curative (C) | 2019-05-21 | 2019-05-28 | CNS LGG 2004 03 vinc weekly+ carbo | 02 | null | CLOFARABINE + CYTARABINE | 101083728 |
| 240002441 | 240007102 | 1.54 | 60 | Curative (C) | 2016-05-25 | 2016-05-25 | Cytarabine High Dose | 02 | N | RUXOLITINIB | 101005267 |
| 240002442 | 240007103 | 1.71 | 81.4 | null | null | 2018-06-12 | R IVAC | N | null | ALL ALLR3: S/IR CONS | 100798552 |
| 240002444 | 240007105 | 1.7 | 69 | null | 2019-04-11 | 2019-04-18 | ICE-R | 02 | N | AML MYECHILD 01 A MITOZANTRONE/CYTARABINE | 100239144 |
| 240002445 | 240007106 | 1.7 | 77 | Palliative (P) | null | 2017-01-17 | Trial Unspecified | null | N | CNS LGG 2004 03 VINC WEEKLY+ CARBO | 100221166 |
| 240002446 | 240007107 | 1.6 | 94.9 | Palliative (P) | 2020-08-14 | 2020-10-19 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | Y | N | CARBOPLATIN + VINCRISTINE | 101836967 |
| 240002447 | 240007108 | 0 | 96 | null | 2016-06-09 | 2016-06-12 | null | 02 | null | CYTARABINE + FLUDARABINE + IDARUBICIN | 100679385 |
| 240002448 | 240007109 | 1.64 | 113 | Curative (C) | 2018-12-11 | 2018-12-11 | Trial Unspecified | 02 | null | BORTEZOMIB + THALIDOMIDE | 100616707 |
| 240002452 | 240007111 | 1.54 | 91.7 | Curative (C) | 2016-08-28 | 2016-09-05 | null | 02 | null | VENETOCLAX | 100463616 |
| 240002453 | 240007112 | 1.57 | 60 | 03 | 2016-11-01 | 2016-11-04 | ALL UKALL2011 Maintenance A1 | 02 | N | BLEOMYCIN + CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + PROCARBAZINE + VINCRISTINE | 100564439 |
| 240002454 | 240007113 | 1.71 | 50.3 | null | 2015-11-21 | 2015-11-23 | CVP | 02 | null | MELPHALAN | 100455766 |
| 240002458 | 240007115 | 1.73 | 110.5 | null | null | 2018-02-01 | FLAIR trial | null | null | CLADRIBINE + RITUXIMAB | 101461048 |
| 240002460 | 240007116 | 1.79 | 49.2 | 03 | 2021-05-24 | 2021-05-24 | null | 02 | N | AML MYECHILD 01 A MITOZANTRONE/CYTARABINE | 101381163 |
| 240002462 | 240007117 | 1.75 | 67.3 | null | 2019-12-25 | 2019-12-31 | AML Interim Guidelines FLAG-Ida | 02 | N | PEG INTERFERON | 100078568 |
| 240002465 | 240007118 | 1.65 | 14.2 | Palliative (P) | null | 2019-11-28 | Cladribine (subcut) 5 days | 02 | N | RUXOLITINIB | 100420854 |
| 240002466 | 240007119 | 1.73 | 73.2 | null | null | 2019-04-06 | Alemtuz+Fludara+Melphalan RIC MUD | null | null | ALL INT GDE 2019 MAINTENANCE | 100804400 |
| 240002467 | 240007120 | 1.74 | 58.6 | null | 2017-11-29 | 2017-11-29 | ANAGRELIDE | 02 | null | CYTARABINE HIGH DOSE | 101403697 |
| 240002472 | 240007122 | 1.67 | 78 | null | 2020-01-06 | 2020-01-07 | ALL UKALL2011 Std BFM Cons B | 02 | null | IBRUTINIB | 100991995 |
| 240002473 | 240007123 | 1.62 | 88 | 03 | null | 2021-02-18 | Imatinib 400mg | null | N | CLADRIBINE | 101350298 |
| 240002477 | 240007125 | 1.73 | 68.9 | 03 | 2016-12-20 | 2016-12-21 | Imatinib 400mg | N | N | IBRUTINIB | 100865088 |
| 240002478 | 240007126 | 1.69 | 61 | Curative (C) | 2017-05-31 | 2017-06-04 | DABRAFENIB | 02 | N | IBRUTINIB + RITUXIMAB | 100059700 |
| 240002479 | 240007127 | 1.86 | 79.4 | null | 2019-06-24 | 2019-06-24 | DA-EPOCH-R | 02 | null | PACLITAXEL | 100574708 |
| 240002482 | 240007128 | 1.92 | 70.15 | Curative (C) | 2019-04-16 | 2019-06-11 | Midostaurin | 01 | N | ANAGRELIDE | 101404661 |
| 240002484 | 240007129 | 1.67 | 81.6 | null | null | 2019-01-11 | null | null | null | R-GEM-P | 100246627 |
| 240002486 | 240007130 | 1.73 | 77 | null | 2018-04-18 | 2018-04-30 | AML Interim Guidelines FLAG-Ida | 02 | N | AML MYECHILD | 101706950 |
| 240002487 | 240007131 | 1.59 | 58.9 | null | null | 2018-01-03 | RUXOLITINIB | null | null | DA | 100475949 |
| 240002492 | 240007135 | null | 71.7 | null | 2016-02-09 | 2016-03-10 | null | null | null | BENDAMUSTINE + POLATUZUMAB VEDOTIN + RITUXIMAB | 101353212 |
| 240002493 | 240007136 | 1.32 | 45.3 | Curative (C) | 2018-06-24 | 2018-08-19 | null | 02 | N | NOT MATCHED | 100416742 |
| 240002495 | 240007138 | 1.64 | 75 | Palliative (P) | null | 2020-07-26 | ESHAP | N | N | CYTARABINE + FLUDARABINE + IDARUBICIN | 100103582 |
| 240002496 | 240007139 | 1.8 | 85.15 | null | null | 2017-10-18 | null | null | null | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 101701485 |
| 240002501 | 240007142 | 1.78 | 73.2 | null | 2021-05-16 | 2021-06-09 | FLAIR trial | N | null | ACALABRUTINIB | 100078158 |
| 240002504 | 240007144 | 1.65 | 84.6 | null | 2019-09-27 | 2019-09-27 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | null | TRIPLE INTRATHECAL | 101763300 |
| 240002506 | 240007145 | 1.7 | 55 | null | null | 2016-10-15 | null | 02 | null | TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 101199436 |
| 240002507 | 240007146 | 1.75 | 77.75 | null | 2019-06-12 | 2019-06-12 | CLADRIBINE | 02 | null | AMADEUS TRIAL | 101629289 |
| 240002509 | 240007147 | 1.64 | 68.2 | Palliative (P) | null | 2022-03-03 | null | 02 | N | NILOTINIB | 101574771 |
| 240002510 | 240007148 | 1.68 | 98.9 | Curative (C) | 2019-05-12 | 2019-05-12 | AML MyeChild 01 FLA-Idarubicin | 02 | null | ANAGRELIDE | 101776866 |
| 240002512 | 240007150 | 1.64 | 59.2 | null | 2018-10-19 | 2019-01-04 | IBRUTINIB | null | null | AML DOWNS HAM | 100149522 |